Travis Jackson

Travis Jackson

Polsinelli

Contact  |  View Bio  |  RSS

Latest Publications

Share:

MedPAC Report Recommends Reduction in Medicare Part B Payments to 340B Hospitals

On March 15, 2016, the Medicare Payment Advisory Commission (MedPAC) released its latest report to Congress that included 340B Implications for Medicare Part B Drugs along with a quick fact sheet regarding the report. Key...more

3/21/2016 - CMS Health Care Providers Hospitals Medical Reimbursement Medicare Part B MedPAC Provider Payments Section 340B

Orphan Drug Ruling Disrupts the 340B Program

On Wednesday, the United States District Court for the District of Columbia issued its highly anticipated opinion regarding the 340B orphan drug litigation. The Court ruled in favor of PhRMA, a trade association that...more

10/20/2015 - Biopharmaceutical Covered Entities GPOs Health Care Providers Healthcare Hospitals HRSA Orphan Drugs Pharmaceutical Industry PHRMA Prescription Drugs Rural Health Care Providers Section 340B Summary Judgment

Summary of Key 340B Omnibus Guidance Proposals

As noted in our previous client alert, the Health Resources and Services Administration (“HRSA”) released its highly anticipated proposed 340B Drug Pricing Program Omnibus Guidance (“Guidance”). The Guidance offers updated...more

9/17/2015 - AIDS Covered Entities Fee-for-Service GPOs Healthcare HRSA Managed Care Contracts Medicare Pharmaceutical Industry Prescription Drugs Section 340B

Breaking News: Proposed 340B Omnibus Guidance Released

The Health Resources and Services Administration (“HRSA”) released an advanced copy of its long-awaited proposed 340B Omnibus Guidance (“Guidance”) today. The document can be found here. Polsinelli is currently reviewing the...more

8/28/2015 - Covered Entities Drug Pricing Health Care Providers Healthcare HRSA Pharmaceutical Industry Physicians Rural Health Care Providers Section 340B

340B Program Change on the Horizon? OMB Completes Review of the 340B Omnibus Guidance

Safety-net providers, manufacturers, members of Congress, and other stakeholders have been tracking the status of the Health Resources and Services Administration’s (“HRSA”) draft 340B Omnibus Guidance closely as it promises...more

8/19/2015 - Civil Monetary Penalty Drug Pricing Healthcare Hospitals HRSA OMB Patients Pharmaceutical Industry Pharmacies Section 340B

IRS Clarifies Requirements for Listing Providers in Financial Assistance Policies

On June 26, 2015, the Internal Revenue Service (IRS) released Notice 2015-46, which clarifies the requirement in the Treasury Regulations under Section 501(r)(4) that a hospital's financial assistance policy (FAP) must...more

7/9/2015 - Affordable Care Act Compliance Financial Assistance Policy Health Care Providers Healthcare Hospitals IRS

Special Update: OPA Sends 340B Program Omnibus Guidelines to Office of Management and Budget

On Wednesday, May 6, the Health Resources and Services Administration, Office of Pharmacy Affairs (“OPA”) forwarded a draft copy of its 340B Program Omnibus Guidelines (“Guidelines”) to the Office of Management and Budget for...more

5/8/2015 - Medicaid OMB Pharmaceutical Industry PHSA Prescription Drugs Section 340B

RESCHEDULED: 340B in the Spotlight: Congress Offers Webcast of Upcoming Hearing Regarding the 340B Drug Pricing Program

The House Energy & Commerce Health Subcommittee on Health hearing entitled, “Examining the 340B Drug Pricing Program”, originally scheduled for Thursday, March 5th has been RESCHEDULED for March 24, 2015 at 10:00 a.m. EST. ...more

3/23/2015 - Congressional Investigations & Hearings Healthcare Prescription Drugs Section 340B

340B in the Spotlight This Thursday: Congress Offers Webcast of Upcoming Hearing Regarding the 340B Drug Pricing Program

Thursday, March 5th at 10:00 a.m. EST, the House Energy & Commerce Health Subcommittee on Health will hold a hearing entitled, “Examining the 340B Drug Pricing Program.” The purpose of the hearing is to review the...more

3/4/2015 - Health Care Providers Healthcare Pharmaceutical Industry Prescription Drugs Section 340B

340B State of Affairs – Study Reveals Benefits to Vulnerable, Chronically Ill Patients

The 340B provider community received welcome news from a recent study published by Health Affairs, which published a long-awaited report analyzing 12 months of outpatient prescription data to identify trends in 340B contract...more

12/3/2014 - HHS HRSA Market Research Pharmaceutical Industry Pharmacies Prescription Drugs Proposed Regulation Section 340B

Breaking 340B News: HRSA Withdrew its Much-Anticipated 340B Mega-Reg

On Thursday, HRSA formally withdrew its much-anticipated 340B Mega-Reg from the rulemaking process, effectively abandoning its effort to overhaul existing 340B program guidance through new regulations. Commander Krista...more

11/18/2014 - HRSA Rulemaking Process Section 340B

Recent 340B Orphan Drug Decision May Have Widespread Implications

In This Issue: - Orphan Drug Rule Background - PhRMA Sues to Block the Orphan Drug Rule - District Court Says HHS Overstepped Its Authority and Invalidates Orphan Drug Rule - Implications on the...more

6/4/2014 - HHS Orphan Drugs Patent Litigation Patents Pharmaceutical Industry Pharmaceutical Patents PHRMA Prescription Drugs Section 340B

12 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×